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BACKGROUND: Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16
E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well
explored.
METHODS: Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion
proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N¼40), partners of patients with
HPV16þ OPC (N¼11), and healthy controls (N¼50).
RESULTS: Oropharyngeal carcinomas patients with known virus-like capsid particleþ Abs had elevated serum Abs to HPV16 E1, E2,
E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with
controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each Pp0.01). In a validation cohort,
HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (Pp0.02) and partners of
OPC patients (Pp0.01).
CONCLUSION: Patients with HPV16þ OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for
HPV-associated OPC.
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Approximately 20 million Americans are currently infected with
human papillomavirus (HPV), and another 6.2 million people
become newly infected each year (Dunne et al, 2007; Markowitz
et al, 2009). Genital HPV is a common sexually transmitted
disease, with prevalent infection in a quarter of all adult women
(Dunne et al, 2007; Markowitz et al, 2009). Recently, HPV infection
has been identified as an aetiologic cause of a rapidly increasing
subset of oropharyngeal carcinomas (OPC) (Loning et al, 1985;
Andl et al, 1998; Wilczynski et al, 1998; Mork et al, 2001; van
Houten et al, 2001; Ringstrom et al, 2002). There are an estimated
82962 HPV-associated OPC cases per year worldwide. Orophar-
yngeal carcinomas is increasing in incidence in North America and
HPV DNA is now found to be present in 50–70% of OPC cases in
North America and to a lesser extent in Europe. Contrary to other
HPV-related malignancies, HPV16 type accounts for 85–90% of
HPV-associated cases of OPC (D’Souza et al, 2007; Marur et al,
2010). Human papillomavirus type 16-associated OPC has a
significantly improved clinical outcome and responsiveness to
therapy (Gillison et al, 2000; Schwartz et al, 2001; Furniss et al,
2007; Chung and Gillison, 2009; Ang et al, 2010; Posner et al, 2011).
Initial HPV infection induces both systemic and local humoral
immune responses (Dillner et al, 1994; Kirnbauer et al, 1994;
Schwartz et al, 1998). Serum antibodies (Abs) to L1 capsid protein
are induced in 50–70% of infected patients months after HPV
infection and are detectable for years after clearance of the
infection, thus capsid Abs represent a history of lifetime HPV
exposure (Wang et al, 2004; Frazer, 2009). Detection of serum Abs
to HPV16 E6 and E7 are induced in a subset of patients with
invasive cancers (Zumbach et al, 2000; Herrero et al, 2003; Smith
et al, 2007a; Reuschenbach et al, 2008). The frequency of virus-like
capsid particle (VLP), E6, and E7 seropositivity is directly asso-
ciated with the presence of HPV DNA in the tumour (Rosales et al,
2001; Kreimer et al, 2005). Seropositivity for HPV16 E6 or E7 is
strongly associated with the odds of OPC (64% of cases; OR: 58)
(D’Souza et al, 2007), and predicts an improved prognosis (Smith
et al, 2008a). Humoral immunity to other HPV early gene products
has not been well evaluated, and the relationship of early gene Abs
to the pathogenesis and prognosis of OPC and other HPV-related Received 18 January 2011; revised 15 April 2011; accepted 19 April 2011
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scancers has not been established. As the incidence of HPV-related
OPC is predicted to increase over the next three decades, a broader
look at the immune responses to the entire HPV proteome may
yield sensitive biomarkers for early identification of at-risk
populations, prediction of biologic behaviour and therapeutic
outcome, and detection of second HPV malignancies.
We have developed rapid, programmable, multiplexed serologic
assays for the detection of antigen-specific Abs in human sera
(Ramachandran et al, 2004, 2008a,b; Anderson and LaBaer, 2005;
Anderson et al, 2008). This approach uses mammalian in vitro
expression of cDNA’s encoding protein antigens, followed by the
capture of antigens using anti-tag Abs, and subsequent binding
and multiplexed detection of Abs from patient sera. We have
successfully expressed and captured over 15000 different human,
viral, and bacterial proteins for monitoring humoral immunity,
and have adapted this approach for bead-based (Luminex) arrays
(Wong et al, 2009) for high-throughput serologic screening.
Because this approach is based on cDNA rather than on purified
proteins, it allows for greater flexibility and economy in antigen
selection and for epitope mapping.
To evaluate immune responses to HPV proteins as potential
biomarkers for early detection of OPC, we developed a program-
mable Luminex bead array ELISA for the detection of serum Abs to
the HPV16 proteome from patients with HPVþ and HPV  OPC,
partners, and controls. In parallel, we have used in situ hybridi-
sation for the characterisation of HPV16 content in tumours.
The marked heterogeneity of immune responses in the uniform
patient population suggests that there are fundamental biologic
differences in host/viral biology that may impact clinical outcome.
MATERIALS AND METHODS
Study populations
Brown University case/control training dataset Human papillo-
mavirus serology was performed using retrospectively identified
sera from 20 head and neck cancer patients (‘training set’)
collected at Brown University that were known to be positive for
HPV16 (N¼10) or HPV18 (N¼10) Abs defined by the comp-
etitive Luminex immunoassay (cLIA; VLP Abþ) developed by
Merck (West Point, PA, USA) (Smith et al, 2008c). Control sera
(N¼20) were obtained from Brown University and were age (±5
years), residence, and gender matched to cases and processed
simultaneously. Serum samples were collected using a standar-
dised sample collection protocol and stored at  801C until use.
Validation (Dana-Farber Cancer Institute/Johns Hopkins University)
case/control data set To confirm the findings from the training
set, serum from 30 pre-therapy OPC cases and 30 controls,
collected as part of a larger research study, were evaluated. This
included blood from OPC patients at Dana-Farber Cancer Institute
(DFCI, N¼17) and Johns Hopkins University (JHU, N¼13) as
well as healthy anonymous blood donors (N¼30) and partners of
OPC patients (N¼11). Of these samples, 55 were sera and 16 were
plasma (6 of these were obtained at the time of leukopheresis).
HPV16þ healthy control (CDC) dataset We also evaluated
serum from women with documented cervical infection with
HPV16. The sera were obtained from an NCI Early Detection
Research Network biorepository collected from women attending
colposcopy clinics (Rajeevan et al, 2005). A total of 20 serum
samples were identified from subjects that were positive for HPV16
DNA in exfoliated cervical cells using the Roche prototype line
blot assay (reagents provided as a gift from Roche Molecular
Systems, Inc., Pleasanton, CA, USA). All subjects had no cervical
disease (CIN 0) at the time of colposcopy. Written informed consent
was obtained from all subjects under institutional review board
approval.
Gene cloning
Human papillomavirus types 16 and 18 genes E1, E2, E4, E5, E6,
E7, L1, and L2 were obtained by nested PCR. As HPV16 E2
expressed poorly, it was fragmented into N- and C-terminal halves.
An initial PCR was done with gene-specific primers (Supplemen-
tary Table 1) from HPV16 and HPV18 purified plasmid DNA
(American Type Culture Collection, Manassas, VA, USA). Primer
extension PCR was used to add attB sites for recombination
cloning. The att PCR products were inserted into the pDONR221
vector according to manufacturer’s recommendations using BP
Clonase (Invitrogen, Carlsbad, CA, USA) and were converted
to the pANT7_GST vector (Ramachandran et al, 2004) with LR
recombinase (Invitrogen). DNA was prepared with Nucleobond
Xtra Maxi (Macherey-Nagel Inc., Bethlehem, PA, USA) and
sequence confirmed.
Bead array ELISA
SeroMAP carboxylated microspheres (Luminex Corporation,
Austin, TX, USA) from regions #35–44 were coupled at a ratio
of 5mg anti-GST antisera to 1 million beads and the coupling
confirmed as described in Wong et al (2009). Each HPV gene was
expressed as GST-fusion proteins using a single batch of T7
reticulocyte lysate (Promega Corporation, Madison, WI, USA) per
manufacturer’s recommendations with 500ng DNA. Vector and
p21-GST were also expressed as negative controls. The in vitro
transcription/translation (IVTT) products were each captured
onto 2000 microspheres at 40microspheres per ml in PBS-1% BSA.
Protein-bound microspheres were pooled together, then re-
aliquoted to a 96-well filter plate (Millipore Corporation, Billerica,
MA, USA). Microspheres were blocked with 10% each of normal
sera from mouse, rabbit, goat, and rat; 0.5% polyvinyl alcohol
(Sigma-Aldrich, St Louis, MO, USA); 0.8% polyvinylpyrrolidone
(Sigma-Aldrich); and 2.5% Chemicon (Millipore) in PBS-1% BSA.
Test sera were diluted 1:80 in blocking buffer and incubated
with the washed beads overnight at 41C while shaking. Biotin-
conjugated goat anti-human IgG antibody (4mgml
–1, Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and
streptavidin-R-PE (4mgml
–1, Molecular Probes, Inc., Eugene, OR,
USA) were added. To control for non-specific and GST-specific
autoantibody background, the ratio of median fluorescence
intensity (MFI) for individual HPV-specific Abs to the MFI for
the control p21-GST antigen was measured. To determine protein
expression, GST-protein tags were detected with anti-GST mono-
clonal Ab (Cell Signaling Technology, Danvers, MA, USA) and
PE-conjugated goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories).
Tumour HPV DNA detection by PCR
DNA was isolated from paraffin-embedded tumour tissue
(QIAamp DNA mini kit, QIAGEN, Valencia, CA, USA). Polymerase
chain reaction was performed using a procedure developed
by Access Genetics (Minneapolis, MN, USA), which amplifies the
HPV L1 domain with degenerate forward and reverse primers
(Agoston et al, 2010). Each 50ml reaction contained 1.25 units
of Taq polymerase (Fisher Scientific, Pittsburgh, PA, USA),
10mmoll
–1 Tris–HCL, pH 9.0, 50mmoll
–1 KCl,4.6mmoll
–1
MgCl2, 0.02mmoll
–1 of each deoxyribonucleotide triphosphate,
11pmol of each primer, and 100–500ng of DNA. The reactions
were cycled at 951C for 2min, followed by 20s each of 951C then
551C and 30s at 721C. The final cycle was 721C for 5min and
held at 151C until analysed. As a control for DNA quality, the DNA
was separately amplified with primers to the b-globin gene
(Forward: AGAATGGTGCAAAGAGGCATGA, Reverse:GCATCAG
TGTGGAAGTCTCAGG; 503bp product). The DNA samples that
were positive for HPV were genotyped by restriction endonuclease
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sfragment analysis. The HPV PCR products were digested in three
separate reactions using PstI, Rsa I, and Hae III. All PCR products
were resolved on 1mm, 5% acrylamide gels, stained with ethi-
dium bromide, and visualised by transillumination. The pattern of
restriction fragment-length polymorphism of each sample was
compared with the Access Genetics database to determine the HPV
genotype (Ralston Howe et al, 2009).
Statistical analysis
Serum HPV Ab levels were measured as MFI using the Luminex200
IS 2.3 software. Fifty events were counted for each bead region. To
establish ELISA cutoff values, the training set control sera (N¼20)
and the validation control sera (N¼30) were used. An MFI ratio
4(the average þ 3 s.d.) of all control samples was designated
positive. These levels were E1: 5.4, NE2: 8.5, CE2: 6.8, E4: 2.3, E5:
4.2, E6: 9.0, E7: 6.6, L1: 9.5, and L2: 8.0. To determine the
variability of serum detection for each HPV antigen, test serum
from a single OPC patient (tumour HPV16þ confirmed by PCR)
was assayed in duplicate on four separate days for each of the
HPV16 antigens. Intra-assay and inter-assay variability was deter-
mined by calculating the coefficient of variation (CV, (s.d./mean)
 100). Heat maps and cluster analysis were done using Multi-
Experiment Viewer software (Saeed et al, 2003).
RESULTS
HPV16 bead array ELISA
A schematic of the HPV16 bead array ELISA for the detection of
Abs in patient sera to the HPV16 antigens is shown in Figure 1A.
The GST expression of all HPV16 (E1, NE2, CE2, E4, E5, E6, E7, L1,
and L2), as well as HPV18 E7-fusion proteins are shown in
Figure 1B. Protein expression was defined as over 10% greater than
the average vector control signal, indicated by the dotted line
(Figure 1B), and is consistent with observed protein expression
levels from 470 IVTT-expressed antigens on bead arrays (Wong
et al, 2009) and 47000 antigens on slide-based microarrays
(Ramachandran et al, 2008b). The cutoff value was 3458 MFI with
signals ranging between 2997 and 8525 MFI (mean¼5870).
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Figure 1 HPV bead array ELISA. (A) Schematic of bead array ELISA for the detection of HPV Abs. Individual HPV cDNA’s encoding full-length HPV
antigens are expressed as C-terminal GST-tagged proteins using reticulocyte lysate. The expressed protein is then captured onto Luminex microspheres via
anti-GST antibody that is coupled onto the beads. For IgG detection from sera, beads tagged with HPV antigens are mixed and added to human sera. Bound
human IgG is detected with biotin-anti-IgG and streptavidin-PE. (B) GST expression of HPV16 gene products and HPV18 E7. GST expression of N- and
C-terminal HPV16 E2 fragments is shown in the right panel. GST protein on the beads was measured by addition of anti-GST-PE antibody as mean
fluorescence index (MFI). Background protein expression (vector mean plus 10%) is indicated by the dotted line. (C) Antibodies to HPV16 early gene
proteins are detected at 41:10000 dilution in two OPC patient sera. Patient sera were diluted two-fold from 1:40 to 1:40960, and IgG Abs to
HPV-derived proteins and p21-GST control protein are shown in order of peak MFI signal intensity. Inserts: zoom-in views of (i) and (ii), respectively.
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sHuman papillomavirus type 16 E2 was considered a non-expressor
and fragmented into N- and C-terminal halves with strong
expression of both fusion proteins (Figure 1B, right).
In prior studies, we determined that IVTT-based protein display
ELISAs demonstrate comparable sensitivities and limits of
detection as recombinant protein ELISA for the detection of both
p53- and EBV-specific Abs (Anderson et al, 2008; Ramachandran
et al, 2008a) and can multiplex eight antigen-specific Abs with
long-term stability and without loss of sensitivity (Wong et al,
2009). The reproducibility of Abs to all HPV16 gene products
was measured in duplicate using serum from an HPV16þ OPC
patient four times over a 1-week span. Intra-assay CV’s ranged
from 0.19 to 22.4% and inter-assay CV’s ranged from 7.6 to 21.3%
(Supplementary Table 2). Positive control sera for E1, E2, and E7
Abs were included with every assay, with 100% accuracy measured
for 8–16 assays over 12 months using the cutoff values established
(see Materials and Methods).
High-titre Abs to HPV16 antigens are detected in
representative OPC patient sera
IgG Abs specific for HPV-derived proteins were detected in two
representative serially diluted OPC patient sera (Figure 1C). For
both sera, Abs to E1 and E7 were detected with the highest signals,
with peak signal detection at a serum dilution of 1:80, which has
also been observed with the highly immunogenic EBNA-1 and p53
antigens using the bead array ELISA (Wong et al, 2009). Half-
maximal signal occurred at a serum dilution of 1:640, and E1- and
E7-specific Abs could be detected at 41:10000 dilution. Anti-
bodies to L2, E5, and the negative control p21 antigen were not
detected, with raw signals between 28.5 and 548 MFI. Median
fluorescence intensity of p21-GST did not differ between case and
control samples in the training and validation sets (P¼0.524).
For all subsequent studies, the MFI ratio of specific HPV Ab to
p21-GST was used to control for non-specific protein binding.
Serum Abs to HPV16 genes in OPC cases compared with
controls: training set
We initially selected a retrospective training set of sera from
patients known to have Abs to HPV16 VLP or HPV18 VLP by the
highly sensitive Merck cLIA assay, which were predicted to have
higher levels of Abs to HPV-derived early genes. The charac-
teristics of patients with HPV-associated OPC and age- and
gender-matched controls (training set) are shown in Table 1.
History of alcohol and tobacco use was similar among cases and
controls. In all, 18 of 20 of the cases had OPC cancer; 2 had laryngeal
cancer; and 16 of 20 had stage III/IV cancers. The status of HPV viral
DNA in the tumour for the training set cases is not known.
Among the training set of 20 head and neck cancer sera and 20
controls, HPV16-specific Abs to E1, E4, E6, E7, L1, and L2 were
significantly more common among OPC cases with HPV16 VLP
Abs than in healthy controls (each Pp0.05) (Figure 2; Table 2).
There was no specific detection of E5 Abs in cases compared with
controls. To control for exposure to other HPV types, 10 OPC
patients with known HPV18 VLP Abs, but not HPV16 VLP Abs in
the sera, were also evaluated. The status of HPV viral DNA in the
tumours was not known (i.e., these were not known HPV18þ
tumours); these patients had evidence of prior infection with
HPV18 based only on VLP Abs. This cohort had no evidence of
HPV16-specific Abs to E1, E4, E6, or E7. A subset of patients with
HPV18 VLP had Abs to NE2 and CE2, suggesting that there is viral
type-specific cross-reactivity of this antigen.
Table 1 Characteristics at diagnosis of patients in the training set
Cases (N¼20)
HPV16 VLP+
b HPV18 VLP+
b
Controls
P-value
a
N¼10 N¼10 N¼20 HPV16 VLP+ HPV18 VLP+
N (%) N (%) N (%) vs controls vs controls
Age
47–56 5 (50) 3 (30) 8 (40)
57–68 2 (20) 4 (40) 6 (30)
69–84 3 (30) 3 (30) 6 (30) 0.82 0.83
Sex
Female 1 (10) 5 (50) 6 (30)
Male 9 (90) 5 (50) 14 (70) 0.22 0.28
Ever smoked cigarettes?
Yes 8 (80) 7 (70) 12 (60)
No 2 (20) 3 (30) 8 (40) 0.27 0.59
Number of usual drinks per week
o4 2 (20) 1 (10) 7 (35)
44 8 (80) 9 (90) 13 (65) 0.40 0.14
Stage
III 2 (20) 1 (10)
IV 7 (70) 6 (60)
Unknown 1 (10) 3 (30)
Tumour sub-site
Oral 1 (10) 3 (30)
Pharynx 8 (80) 6 (60)
Larynx 1 (10) 1 (10)
Abbreviations: Abs¼antibodies; cLIA¼competitive Luminex immunoassay; HPV¼human papillomavirus; VLP¼virus-like capsid particle.
aw
2-test.
bAbs to HPV16 or 18 VLP by
cLIA.
HPV16 antibody biomarkers in head and neck cancer
KS Anderson et al
1899
British Journal of Cancer (2011) 104(12), 1896–1905 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTo determine if there was cross-reactive antigenicity between
viral types, Abs to HPV16E7 and HPV18E7 in patient sera were
compared. Patients who had detectable Abs to HPV16E7 did not
have detectable Abs to HPV18E7 (Figure 2). One patient with Abs
to HPV18 VLP also had detectable Abs to HPV18E7. Only 6 out of
10 HPV VLP Abþ patients also had detectable L1 Abs by bead
array ELISA, likely representing display of different antigenic
structures detected in the two assays, or a lower sensitivity of
the bead array ELISA for the detection of L1 Abs. Of the four L1
Ab-negative cases, there was no significant difference in back-
ground p21 MFI compared with the L1 Abþ cases (P¼0.914). No
correlation between HPV16L1 bead array signal intensities and
VLP titre were observed (R¼0.638), likely related to structural
differences in epitope display, which has been observed for
L1-specific epitopes (Vonka et al, 1998).
Serum Abs to HPV16 genes in OPC cases compared with
controls: validation set
As the training set sera were specifically selected for head and neck
cancer patients with L1-specific Abs, we evaluated OPC patients
at DFCI and JHU with unknown serum HPV L1 status, compared
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Figure 2 Specific detection of multiple early gene Abs in 10 patients with HPV16 VLP Abs compared with 20 controls. HPV16 proteins, as well as HPV18
E7 and p21 proteins, were expressed and captured on Luminex beads, and the MFI ratio (MFI (HPV)/MFI (p21-GST)) of IgG detected in sera is shown.
Training set serum IgG responses were measured in age- and sex-matched healthy controls (‘Controls’), patients with HPV16 VLP Abs (‘HPV16 VLPþ’),
and patients with HPV18 VLP Abs (‘HPV18 VLPþ’). HPV16-specific Abs to E1, E4, E6, E7, and L1 proteins (but not E5 and L2) are detected in HPV16 VLP
Abþ patients compared with controls or patients with HPV18 VLP Abs. Top middle and top right: HPV16 NE2 and CE2 Abs are also detected in cases
with HPV18 VLP Abs. Bottom right middle and far right: HPV16 E7 Abs do not cross-react with HPV18 E7.
Table 2 Serum HPV antibody levels in patients with oropharyngeal cancer compared with non-cancer controls (training set)
Antibodies
MFI ratio
a
HPV16 VLP+ OPC cases (N¼10) HPV18 VLP+ OPC cases (N¼10) Controls (N¼20)
HPV16 Mean (Range) Mean (Range) Mean (Range)
E1 50.7
b (2.0–159) 2.2 (0.2–4.8) 2.1 (1.1–3.3)
NE2 7.2 (0.1–42) 14.7
c (0.8–52) 1 (0.4–1.4)
CE2 9.2 (0.3–42) 35.8
c (1.4–100) 2.7 (0.6–5.0)
E4 14.6
b (1.2–46) 1.2 (0.1–3.1) 1.3 (0.6–2.1)
E5 1.8 (1.3–2.5) 1.6 (0.1–4.6) 1.9 (0.7–5.5)
E6 11.3
b (2.8–29) 2.2 (0.6–6.3) 2.4 (0.9–7.3)
E7 43.1
c (1.4–173) 2.3 (0.2–6.1) 2.6 (1.0–9.6)
L1 10.3
b (3.5–20) 2.6 (0.7–6.9) 2.6 (1.2–5.1)
L2 4.2
c (2.6–7.7) 2.1
c (0.4–6.1) 3 (1.2–5.8)
HPV18
E7 2.5 (1.4–4.3) 16.7 (0.3–154) 1.8 (0.5–2.8)
Abbreviations: HPV¼human papillomavirus; MFI¼median fluorescence intensity; OPC¼oropharyngeal carcinomas; VLP¼virus-like capsid particle.
aMFI ratio of HPV-GST
antigen/p21-GST.
bCompared with controls, Po0.001 (bold).
cCompared with controls, 0.001pPp0.05 unpaired Wilcoxon’s test.
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swith controls. The clinical characteristics of the OPC patients are
shown in Table 3. Human papillomavirus type 16 E1, NE2, CE2, E4,
E6, E7, and L1-specific Abs were significantly more common
among OPC patient sera compared with healthy controls (E1, NE2,
CE2, E4, E6, E7, and L1, each Po0.007) (Figure 3; Table 4). There
was no specific detection of E5 or L2 Abs in cases. In this
unselected cohort, the detection of L1-specific Abs was only 23% (7
out of 30) compared with healthy controls (1 out of 30, 3%).
The HPV Abs most strongly associated with OPC were HPV16E1
(22 out of 30 (73%) of cases vs 1 out of 30 controls), NE2 (25 out of
30 (83%) of cases vs 1 out of 30 controls), CE2 (24 out of 30 (80%)
of cases vs 1 out of 30 controls), and HPV16E7 (19 out of 30 (63%)
of cases vs 0 out of 30 controls), Po0.001. Compared with E1,
E2, and E7 Abs, fewer patients had E4 Abs (13 out of 30 (43%) vs
0 out of 30 controls) or E6 Abs (15 out of 30 (50%) vs 1 out of 30
controls). All 16 patients with known HPV16þ tumours by PCR
had detectable E1, E2, or E7 Abs. Four of the OPC patients had
HPV16-negative tumours by PCR; of these, two had detectable Abs
to both E1 and E7. This may reflect cross-reactivity with other
HPV types, limitations of the HPV PCR assay, or represent HPV16
infection at other sites. As this cohort included a mix of sera and
plasma, a direct comparison of the subset of serum cases and
controls was performed, with the specificity of detection of HPV16
E1, E2, E6, and E7 Abs maintained (Po0.002).
Given the high proportion of adults (470%) having ever been
infected with high-risk (HR) HPV in most populations (Markowitz
et al, 2009), we anticipate that the majority of our healthy controls
have been exposed to HPV at some point. To evaluate the
correlation between Abs to HPV16 early (E) proteins and current
HPV16 infection, we identified 20 healthy controls with known
HPV16 DNA present in cervical exfoliated cells, but with normal
cervical colposcopies (CIN 0; no evidence of cervical disease).
None of these controls had evidence of HPV16 Abs to E1, E2, E6,
or E7 (data not shown), suggesting that the presence of early gene
Abs in cases is not simply a marker of active HPV16 infection.
HPV16 early gene Abs in partners of HPV16þ OPC
patients
The recent identification of HPV-associated OPC has raised the
question of whether healthy partners of these patients, who are
chronically exposed to oncogenic HPV from their partners with
cancer, develop protective immunity to HPV or are at risk for the
subsequent development of HPV-associated malignancies. Anti-
bodies to HPV16 antigens were measured in sera from partners of
patients with OPC (N¼11, 7 partners known to have HPV16þ
tumours; Figure 3). Low-level Abs to each gene product were
detected in sera of one or two partners of patients with known
HPV16þ tumours, with one partner of a patient with HPV16
status unknown having Abs to five different gene products.
HPV16 antibody hierarchical clustering
To determine whether antibody responses to specific HPV early
genes are concordant (are detected in the same patient sera), the
HPV16 antibody responses in the validation set detected by bead
array ELISA were grouped by unsupervised hierarchical clustering
analysis (Figure 4). Distinct patterns of Ab reactivity were
observed. Pattern I were cases with a strong detection of E1, E2,
E7, and E6 Abs. Pattern II consisted of cases with E1 and E2 Abs,
but not E6 and/or E7 Abs. Pattern III were controls and partners
with weak E6 and L1 Abs, suggesting that there is low-level
antibody immunity in this population that may be protective.
Table 3 Characteristics at diagnosis of participants in the validation set
HPV16 E1 Ab
a,b HPV16 E7 Ab
a,b
Cases Partners Positive Negative Positive Negative
N¼30 N¼11 N¼22 N¼8 N¼19 N¼11
N (%) N (%) N (%) N (%) P-value
c N (%) N (%) P-value
c
Age
39–46 3 (10) 3 (27.3) 2 (9.1) 1 (12.5) 2 (10.5) 1 (9.1)
47–56 13 (43.3) 8 (72.7) 9 (40.9) 4 (50) 7 (36.8) 6 (54.5)
57–68 12 (40) 0 (0) 10 (45.5) 2 (25) 8 (42.1) 4 (36.4)
69–84 2 (6.7) 0 (0) 1 (4.5) 1 (12.5) 0.72 2 (10.5) 0 (0) 0.63
Sex
Female 1 (3.3) 11 (100) 1 (4.5) 0 (0) 1 (5.3) 0 (0)
Male 29 (96.7) 0 (0) 21 (95.5) 8 (100) 0.54 18 (94.7) 11 (100) 0.44
Stage
II 3 (10) 1 (4.5) 2 (25) 2 (10.5) 1 (9.1)
III 5 (16.7) 2 (9.1) 3 (37.5) 3 (15.8) 2 (18.2)
IV 21 (70) 18 (81.8) 3 (37.5) 0.04 13 (68.4) 8 (72.7) 0.98
Unknown 1 (3.3) 1 (4.5) 0 (0) 1 (5.3) 0 (0)
Tumor sub-site
Pharynx 25 (83.3) 19 (86.4) 6 (75) 17 (89.5) 8 (72.7)
Larynx 1 (3.3) 0 (0) 1 (12.5) 0.09 0 (0) 1 (9.1) 0.16
Unknown 4 (13.3) 3 (13.6) 1 (12.5) 2 (10.5) 2 (18.2)
HPV16 tumor
Yes 17 (56.7) 14 (63.6) 3 (37.5) 11 (57.9) 6 (54.5)
No 4 (13.3) 3 (13.6) 1 (12.5) 0.74 2 (10.5) 2 (18.2) 0.59
Unknown 9 (30) 5 (22.7) 4 (50) 6 (31.6) 3 (27.3)
Abbreviations: Ab¼antibody; ELISA¼enzyme-linked immunosorbent assay; HPV¼human papillomavirus.
aAb positive or negative by bead array ELISA.
bCutoff ¼ average + 3
s.d. of normals for each antigen.
cw
2-test.
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sDISCUSSION
It is estimated that 75–80% of sexually active persons in the
United States will be infected with HR HPV in their lifetime
(Dunne et al, 2007). Although effective HPV-prevention vaccines
targeting the L1 capsid protein are currently available, the majority
of people over the age of 21 has already been infected with HR
HPV, either genitally or orally, and may, therefore, remain at risk
of OPC. Clinical biomarkers such as HPV-specific Abs to identify
HR individuals infected with oncogenic HPV types could have
significant clinical impact and long-term health implications.
The detection of serologic immunity to HPV infections has been
hampered by the lack of standardised assays for antibody
detection to the targets of natural immunity (Ferguson et al,
2009). Antibodies to capsid proteins have been measured by ELISA
to conformationally intact VLPs, directly conjugated (Opalka et al,
2003; Dias et al, 2005) or indirectly conjugated via heparin (Faust
et al, 2010) to Luminex microspheres for multiplexed detection of
Abs to different HPV capsid types. To detect Abs to HPV16 E6 and
E7, Escherichia coli-derived proteins have been detected by ELISA
(Di Bonito et al, 2006) or adhered to Luminex beads (Waterboer
et al, 2005; Reuschenbach et al, 2008) for multiplexed detection
from single serum samples. Protein arrays displaying printed
E. coli-derived HPV proteomes have recently been used to identify
E7-specific Abs in cervical cancers (Luevano et al, 2010). However,
expression and purification of proteins in non-mammalian
systems may result in altered antigenic structure of viral proteins.
We have developed a novel assay for the detection of HPV16-
specific IgG Abs in human sera. We demonstrate that Abs to
multiple HPV16-derived early proteins, in particular E1, E2, E6,
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Figure 3 Specific detection of multiple early gene Abs in untreated OPC patients, but not partners. The MFI ratio of HPV16 proteins to p21 protein
detected in sera is shown. The validation set serum IgG responses were measured in an independent set of healthy controls (‘Controls’, N¼30), OPC
patients (‘Cases’, N¼30), and partners of OPC patients (N¼11). HPV16-specific Abs to E1, E2, E4, E6, and E7, and L1 proteins are specifically detected in
patients compared with controls.
Table 4 Serum HPV antibody levels in patients with oropharyngeal cancer compared with non-cancer controls (validation set)
Partners N¼11 OPC cases N¼30 Controls N¼30
HPV16 Antibodies MFI ratio
a (Range) #Ab+ (%) MFI ratio
a (Range) #Ab+ (%) MFI ratio
a (Range) #Ab+ (%)
E1 3.6 (1.5–13.2) 1 (9) 57.5
b,c (1.7–188.7) 22 (73) 1.9 (0.3–8.1) 1 (3)
NE2 2.6 (0.7–17.8) 1 (9) 33.3
b,c (0.8–84.2) 25 (83) 1.7 (0.6–17.2) 1 (3)
CE2 3.2 (1.0–13.1) 1 (9) 35.4
b,c (0.9–83.4) 24 (80) 2.5 (1.0–7.6) 1 (3)
E4 1.5 (0.4–6.0) 2 (18) 12.4
d,c (0.6–77.9) 13 (43) 1.0 (0.4–1.8) 0 (0)
E5 4.3 (0.6–16.5) 2 (18) 1.5
d (0.8–5.8) 1 (3) 1.1 (0.3–4.4) 1 (3)
E6 4.2 (0.9–9.6) 1 (9) 11.4
e,c (1.2–38.2) 15 (50) 2.9 (0.5–10.6) 1 (3)
E7 4.9 (0.8–16.6) 2 (18) 55.2
e,c (1.3–207.7) 19 (63) 1.4 (0.4–3.5) 0 (0)
L1 4.8 (0.8–17.2) 1 (9) 7.9
d (1.0–39.8) 7 (23) 3.3 (0.5–11.1) 1 (3)
L2 4.4 (1.1–21.3) 1 (9) 3.5
d (1.3–10.9) 2 (7) 2.3 (0.4–12.7) 1 (3)
Abbreviations: Ab¼antibody; HPV¼human papillomavirus; MFI¼median fluorescence intensity.
aMFI ratio of HPV-GST antigen/p21-GST.
bCompared with partners, Po0.001.
cCompared with controls, Po0.001 (bold).
dCompared with partners, 0.001pPp0.05 unpaired Wilcoxon’s test.
eCompared with controls, 0.001pPp0.05.
HPV16 antibody biomarkers in head and neck cancer
KS Anderson et al
1902
British Journal of Cancer (2011) 104(12), 1896–1905 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sand E7, are present in pre-treatment sera of patients with incident
HPV16þ OPC, but not in healthy controls or in a limited set of
partners of patients with HPV16þ OPC cancer. Human papillo-
mavirus type 16 E1 and E2 Abs, in particular, were detected in a
small subset of patients who were negative for HPV16 E6 and E7
Abs, suggesting that inclusion of these serologic biomarkers in
screening with E6 and E7 Abs may increase sensitivity and speci-
ficity of detection of infected patients. Human papillomavirus-
specific Abs to E1, E2, and E7 were associated with the detection
of HPV16 DNA within tumours in this small group and will need
to be verified in larger cohorts. Antibodies to E2, in particular,
may cross-react with other HPV types. Assays for the presence
of HPV16 DNA in archived tumour samples has been evolving;
for these studies, the assay was performed by experienced
laboratories across the study sites and was performed within the
past 12 months.
Of interest, these studies demonstrate that there is significant
heterogeneity in the serologic response to HPV, even among
patients with HPV16 detected in the tumour. We have not
identified clinicopathologic criteria that are associated with the
presence of patterns of HPV16-specific early gene Abs in this
preliminary study, although male gender, younger age, and tumour
burden have been associated with increased E6/E7 seropositivity
(Smith et al, 2008b, 2010). Other studies have detected Abs to E6 or
E7 in 65–70% of HPV16þ OPC patients, and are associated with
improved clinical outcome (Smith et al, 2008a, 2010). In our
findings, immune responses to the E6 antigen in patients are less
frequent in OPC cases (50%) than reported and of much lower
titre compared with Abs to E1/E2/E7. This may reflect technical
differences in antigenic display between our serologic assay
and the assay developed in the Pawlita laboratory (Waterboer
et al, 2005); the assays have not been directly compared. While we
do not observe cross-reactivity between HPV16 E7 and HPV18 E7
(the two dominant HPV types in OPC cancer), further studies
correlating serology with the viral type detected in tissue will
be needed.
In cervical cancer, Abs to 16E6 and 16E7 develop late in the
course of disease and have been shown to correlate with disease
response (Ravaggi et al, 2006). In an extensive Scandinavian
study of pre-diagnostic sera collected 0.5–20 years before
diagnosis of cervical cancer (N¼178), 16E6 and 16E7-specific
IgG were detected in 7% of cases with a relative risk (odds ratio) of
2.7, found 0.5–5 years before diagnosis (Lehtinen et al, 2003). This
suggests that serology of the early HPV genes, in particular, may be
detected prior to the development of overt malignancy. The utility
of HPV Abs to predict increased risk of OPC have not been well
evaluated.
The previously unreported E1- and E2-specific Abs in our
cohort is striking because of both the high titre and high frequency
in OPC patient sera, which improves the sensitivity of detection
from 70% to 100% of HPV16þ OPC when combined with E6
and/or E7 Abs. Early studies demonstrated low immunoreactivity
to an E1-derived peptide in cervical cancer sera (Dillner et al,
1995) and weak E1 Abs were identified in cervical cancer (Luevano
et al, 2010); to our knowledge, Abs to E1 or E2 have not otherwise
been described in cervical cancer nor in OPC. E1 proteins are
essential origin recognition proteins for viral replication, binding
to specific DNA elements and assembling into hexameric helicases
(Wilson et al, 2002). Integration of HPV into the host genome
results in disruption of E1/E2 expression and loss of repression of
E6/E7 (Chung and Gillison, 2009). As a result, E1- and E2-specific
Abs may develop prior to Abs to E6/E7 and might prove useful for
early identification of risk.
Human papillomavirus antibody signatures may provide a
rapid, convenient and inexpensive screening method for assessing
the HPV status of suspected or known malignancy. Human
papillomavirusþ OPC is a strong, independent factor for imp-
roved prognosis (Gillison et al, 2000; Schwartz et al, 2001; Furniss
et al, 2007; Chung and Gillison, 2009; Ang et al, 2010), and HPV
status is increasingly being incorporated into clinical trial
stratification. However, current diagnostic studies for viral typing
are cumbersome, expensive, delayed, and require tumour biopsies.
Detection of viral load using oral swabs and rinses is in
development (Summersgill et al, 2001; Smith et al, 2000, 2007b;
Agrawal et al, 2008). It is not yet known whether HPV antibody
signatures will have screening utility and/or have prognostic or
biologic correlates for clinical outcome, monitoring therapy,
or identifying early recurrence. In our uniform cohort of
HPV16þ OPC patients, there is considerable variability in both
the intensity and the specificity of the HPV Ab signatures,
particularly for the early genes, suggesting that these bio-
markers may identify clinically relevant subsets of patients. With
the increasing number of cases of HPV-related oropharynx cancers
occurring in North America and Europe, HPV cancer risk and
prevention strategies will become an important part of routine
medical care.
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Figure 4 Unsupervised hierarchical clustering of HPV16-specific Abs of validation set patient, partner, and control sera. There is a subset of patients
(group I) with multiple HPV-specific Abs, including E1, E2, E6, and E7. Another subset (group II) has E1 and E2, but low or absent E7- and/or E6-specific Abs.
There is a subset (group III) of healthy controls with increased (but weak) levels of E6 and L1 Abs.
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